Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.7M | $10.0M | $5.00M | $8.00M | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $235M |
| Revenue growth | — | -40.1% | -50.0% | 60.0% | 837.5% | -15.8% | -83.7% | 66.8% | 432.0% | 157.0% |
| Operating income | -$3.02M | -$28.8M | -$66.7M | -$107M | -$23.9M | -$56.8M | -$115M | -$164M | -$115M | $47.9M |
| Operating margin | -18.1% | -287.8% | -1334.4% | -1342.9% | -31.8% | -89.9% | -1119.4% | -958.3% | -125.9% | 20.4% |
| Net income | -$4.26M | -$30.1M | -$61.7M | -$97.3M | -$19.9M | -$57.8M | -$129M | -$164M | -$145M | -$13.2M |
| Net margin | -25.5% | -300.7% | -1233.1% | -1216.7% | -26.6% | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| EPS (diluted) | -$1.62 | -$1.52 | -$2.50 | -$3.60 | -$0.73 | -$2.11 | -$4.57 | -$6.08 | -$5.12 | -$0.46 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.03M | -$19.4M | -$48.5M | -$69.5M | -$14.2M | -$45.9M | -$73.6M | -$121M | -$135M | $19.7M |
| Capital expenditures | $50.0K | $290K | $1.06M | $805K | $569K | $1.37M | $358K | $807K | $358K | $87.0K |
| Free cash flow | -$9.08M | -$19.7M | -$49.6M | -$70.3M | -$14.7M | -$47.3M | -$74.0M | -$122M | -$136M | $19.6M |
| Share buybacks | $1.00K | $0.00 | $0.00 | — | — | $0.00 | $0.00 | $50.0M | $456K | $68.6M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $51.2M | $81.2M | $114M | $171M | $250M | $496M | $71.3M | $36.0M | $123M | $238M |
| Total assets | $62.2M | $329M | $509M | $435M | $417M | $643M | $610M | $452M | $484M | $364M |
| Shareholders' equity | -$38.2M | $308M | $486M | $405M | $397M | $356M | $262M | $88.1M | $70.9M | $37.2M |
| Retained earnings | -$54.9M | -$85.0M | -$147M | -$244M | -$264M | -$322M | -$450M | -$614M | -$759M | -$773M |
| Shares (wtd avg diluted) | 2.65M | 23.8M | 26.9M | 27.1M | 27.3M | 27.4M | 28.2M | 26.9M | 28.4M | 28.8M |
Every figure is extracted from ANAPTYSBIO, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.